Immunic (NASDAQ:IMUX) Now Covered by Analysts at HC Wainwright

Equities research analysts at HC Wainwright began coverage on shares of Immunic (NASDAQ:IMUX) in a report released on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright also issued estimates for Immunic’s Q4 2024 earnings at ($0.25) EPS.

Other research analysts have also issued research reports about the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partners restated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. B. Riley assumed coverage on shares of Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $11.80.

Immunic Stock Down 3.4 %

NASDAQ IMUX opened at $1.14 on Monday. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The business’s fifty day simple moving average is $1.38 and its 200-day simple moving average is $1.34. The firm has a market cap of $102.69 million, a PE ratio of -0.93 and a beta of 1.88.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick bought 87,300 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now directly owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently bought and sold shares of the company. State Street Corp grew its position in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Immunic during the first quarter worth about $25,000. Jane Street Group LLC grew its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares in the last quarter. Finally, Ikarian Capital LLC grew its position in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares in the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.